Nifty
Sensex
:
:
10906.95
36386.61
1.75 (0.02%)
12.53 (0.03%)

Pharmaceuticals & Drugs

Rating :
53/99

BSE: 532531 | NSE: STAR

517.25
-11.15 (-2.11%)
18-Jan-2019 | 3:59PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  527.30
  •  529.40
  •  504.50
  •  528.40
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1678240
  •  8680.70
  •  828.30
  •  333.30

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 4,625.65
  • 7.31
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 6,842.29
  • 0.39%
  • 1.96

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 30.79%
  • 0.00%
  • 14.10%
  • FII
  • DII
  • Others
  • 0.41%
  • 24.41%
  • 30.29%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 20.01
  • 5.27

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 9.44
  • -1.62

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 67.81
  • 81.53

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 10.11
  • 22.29
  • 25.37

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.06
  • 3.64
  • 2.82

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 22.18
  • 21.20
  • 16.14

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Mar 18
Mar 17
Var%
Dec 17
Dec 16
Var%
Net Sales
732.63
768.66
-4.69%
663.46
657.78
0.86%
664.15
677.13
-1.92%
749.04
729.78
2.64%
Expenses
633.03
660.88
-4.21%
582.68
586.52
-0.65%
577.63
547.52
5.50%
626.17
588.23
6.45%
EBITDA
99.60
107.78
-7.59%
80.78
71.26
13.36%
86.52
129.61
-33.25%
122.87
141.55
-13.20%
EBIDTM
13.59%
14.02%
12.18%
10.83%
13.03%
19.14%
16.40%
19.40%
Other Income
7.73
22.14
-65.09%
10.64
34.46
-69.12%
21.80
62.39
-65.06%
15.67
22.18
-29.35%
Interest
48.48
48.58
-0.21%
44.12
52.42
-15.83%
45.47
47.87
-5.01%
49.78
44.08
12.93%
Depreciation
44.49
37.25
19.44%
42.87
34.49
24.30%
44.34
37.69
17.64%
39.07
30.87
26.56%
PBT
6.97
31.84
-78.11%
-0.51
15.45
-
-3.14
98.81
-
43.37
77.30
-43.89%
Tax
1.61
5.42
-70.30%
-4.27
4.24
-
-3.95
7.91
-
-0.16
23.50
-
PAT
5.36
26.42
-79.71%
3.76
11.21
-66.46%
0.81
90.90
-99.11%
43.53
53.80
-19.09%
PATM
0.73%
3.44%
0.57%
1.70%
0.12%
13.42%
5.81%
7.37%
EPS
-1.34
0.96
-
-0.66
0.06
-
63.54
12.57
405.49%
9.24
20.96
-55.92%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Dec 09
Dec 08
Net Sales
2,809.28
3,338.63
3,826.22
2,862.19
1,195.85
1,340.96
961.76
2,550.04
1,695.84
1,304.77
1,020.33
Net Sales Growth
-0.85%
-12.74%
33.68%
139.34%
-10.82%
39.43%
-62.28%
50.37%
29.97%
27.88%
 
Cost Of Goods Sold
1,335.02
1,378.84
1,281.17
1,502.29
560.49
714.67
491.82
1,264.39
805.65
700.90
524.20
Gross Profit
1,474.26
1,959.80
2,545.05
1,359.90
635.37
626.30
469.94
1,285.66
890.19
603.86
496.13
GP Margin
52.48%
58.70%
66.52%
47.51%
53.13%
46.71%
48.86%
50.42%
52.49%
46.28%
48.62%
Total Expenditure
2,419.51
2,987.89
3,309.30
2,481.62
967.00
1,117.54
861.18
2,059.36
1,369.22
1,117.84
950.87
Power & Fuel Cost
-
51.33
33.87
77.18
16.02
18.56
12.84
54.24
30.23
24.58
30.81
% Of Sales
-
1.54%
0.89%
2.70%
1.34%
1.38%
1.34%
2.13%
1.78%
1.88%
3.02%
Employee Cost
-
434.05
419.16
357.69
172.06
157.18
120.30
302.74
219.57
177.01
176.81
% Of Sales
-
13.00%
10.95%
12.50%
14.39%
11.72%
12.51%
11.87%
12.95%
13.57%
17.33%
Manufacturing Exp.
-
115.97
137.47
119.23
41.37
35.76
44.43
89.60
63.83
45.15
48.93
% Of Sales
-
3.47%
3.59%
4.17%
3.46%
2.67%
4.62%
3.51%
3.76%
3.46%
4.80%
General & Admin Exp.
-
194.38
172.63
198.71
86.25
66.37
58.16
182.12
159.16
86.87
80.59
% Of Sales
-
5.82%
4.51%
6.94%
7.21%
4.95%
6.05%
7.14%
9.39%
6.66%
7.90%
Selling & Distn. Exp.
-
208.85
161.12
129.57
61.37
66.67
39.94
116.07
88.02
73.40
71.81
% Of Sales
-
6.26%
4.21%
4.53%
5.13%
4.97%
4.15%
4.55%
5.19%
5.63%
7.04%
Miscellaneous Exp.
-
604.48
1,103.88
96.95
29.44
58.33
93.69
50.21
2.76
9.92
71.81
% Of Sales
-
18.11%
28.85%
3.39%
2.46%
4.35%
9.74%
1.97%
0.16%
0.76%
1.74%
EBITDA
389.77
350.74
516.92
380.57
228.85
223.42
100.58
490.68
326.62
186.93
69.46
EBITDA Margin
13.87%
10.51%
13.51%
13.30%
19.14%
16.66%
10.46%
19.24%
19.26%
14.33%
6.81%
Other Income
55.84
805.61
398.08
102.37
38.57
60.23
34.20
31.67
69.70
23.57
310.92
Interest
187.85
196.24
183.10
168.17
47.44
108.88
79.45
194.83
146.65
75.91
84.70
Depreciation
170.77
193.93
198.69
131.25
64.03
56.48
30.86
104.30
63.90
49.19
39.90
PBT
46.69
766.17
533.20
183.50
155.95
118.30
24.48
223.22
185.77
85.41
255.78
Tax
-6.77
25.46
51.19
42.45
147.60
40.86
11.15
38.68
45.19
21.90
10.79
Tax Rate
-14.50%
3.52%
10.30%
29.87%
99.35%
44.53%
1.54%
14.18%
24.25%
15.32%
9.39%
PAT
53.46
677.27
399.38
113.21
1.57
50.89
712.39
224.48
122.45
109.68
107.96
PAT before Minority Interest
36.89
697.14
445.58
99.68
0.98
50.89
713.44
234.01
141.18
121.04
104.08
Minority Interest
-16.57
-19.87
-46.20
13.53
0.59
0.00
-1.05
-9.53
-18.73
-11.36
3.88
PAT Margin
1.90%
20.29%
10.44%
3.96%
0.13%
3.80%
74.07%
8.80%
7.22%
8.41%
10.58%
PAT Growth
-70.68%
69.58%
252.78%
7,110.83%
-96.91%
-92.86%
217.35%
83.32%
11.64%
1.59%
 
Unadjusted EPS
70.78
73.81
44.73
13.14
141.85
298.56
121.47
38.65
26.11
26.49
26.91

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Dec 09
Dec 08
Shareholder's Funds
2,454.56
2,748.82
2,657.87
1,144.92
1,006.83
2,026.24
1,371.48
1,282.78
831.07
415.41
Share Capital
89.50
89.42
89.35
59.62
59.57
58.80
58.38
57.74
89.38
89.21
Total Reserves
2,356.00
2,650.55
2,562.75
1,084.50
947.06
1,963.94
1,310.34
1,222.95
724.09
324.41
Non-Current Liabilities
1,908.40
2,048.67
2,760.03
285.79
306.42
900.59
1,132.57
2,012.89
1,459.17
1,306.42
Secured Loans
1,551.09
1,622.87
2,614.88
250.23
274.29
731.15
1,054.31
1,387.39
778.70
566.01
Unsecured Loans
0.23
14.84
12.13
17.16
1.24
0.00
0.00
622.45
678.17
736.00
Long Term Provisions
16.55
25.19
14.45
6.02
16.56
57.25
66.19
0.00
0.00
0.00
Current Liabilities
1,899.30
3,103.87
1,891.98
1,019.94
707.37
1,797.29
2,791.73
923.65
684.15
420.98
Trade Payables
712.07
774.09
775.40
234.41
262.31
463.08
585.04
419.85
445.23
335.64
Other Current Liabilities
129.98
819.08
347.93
502.47
127.27
651.65
1,369.80
305.00
64.64
24.28
Short Term Borrowings
944.39
1,393.96
700.48
203.03
224.56
599.89
684.65
0.00
0.00
0.00
Short Term Provisions
112.86
116.73
68.19
80.03
93.23
82.66
152.24
198.80
174.28
61.06
Total Liabilities
6,416.91
8,034.86
7,360.09
2,469.36
2,096.29
4,795.97
5,342.24
4,491.79
3,232.89
2,323.09
Net Block
2,735.01
2,909.03
2,678.68
701.36
554.53
3,016.72
3,187.64
2,328.27
1,856.59
969.52
Gross Block
3,028.73
3,186.12
2,825.43
1,080.55
907.33
3,514.29
3,644.82
2,626.71
2,080.70
1,189.65
Accumulated Depreciation
293.71
277.09
146.75
379.19
352.80
497.57
457.19
298.44
224.11
220.12
Non Current Assets
3,933.32
4,243.05
3,845.20
1,039.91
787.65
3,383.87
3,711.33
2,521.48
2,282.61
1,575.48
Capital Work in Progress
620.29
780.18
814.88
171.17
99.47
241.44
285.03
191.46
84.66
259.55
Non Current Investment
350.08
315.66
127.19
68.76
41.80
0.00
0.00
1.76
341.36
346.40
Long Term Loans & Adv.
199.64
222.56
201.83
96.72
90.40
118.75
229.99
0.00
0.00
0.00
Other Non Current Assets
28.30
15.62
22.62
1.91
1.45
6.96
8.67
0.00
0.00
0.00
Current Assets
2,483.59
3,791.82
3,514.89
1,429.44
1,308.63
1,410.94
1,625.27
1,960.40
950.29
747.52
Current Investments
311.48
1,279.54
1,213.76
561.29
401.24
0.06
0.00
0.00
0.00
0.00
Inventories
552.02
732.80
613.14
207.68
175.99
442.33
479.93
312.00
233.42
173.12
Sundry Debtors
882.18
995.91
1,032.97
389.96
364.00
483.23
538.44
383.78
420.27
337.51
Cash & Bank
303.33
329.48
311.59
146.88
231.15
165.74
259.73
339.45
91.20
56.95
Other Current Assets
434.59
209.70
245.90
69.18
136.26
319.58
347.17
925.17
205.40
179.94
Short Term Loans & Adv.
295.75
244.39
97.54
54.46
79.06
44.38
91.79
850.18
150.94
99.87
Net Current Assets
584.29
687.95
1,622.91
409.50
601.26
-386.35
-1,166.46
1,036.75
266.14
326.54
Total Assets
6,416.91
8,034.87
7,360.09
2,469.35
2,096.28
4,795.98
5,342.23
4,491.80
3,232.90
2,323.10

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Dec 09
Dec 08
Cash From Operating Activity
187.07
288.14
73.25
83.40
-271.68
134.26
457.10
323.93
89.61
117.75
PBT
705.80
497.14
146.44
992.01
2,889.87
949.49
272.69
186.37
142.94
114.88
Adjustment
-274.51
190.92
345.56
-756.73
-2,775.01
-415.93
113.84
178.94
42.76
19.47
Changes in Working Capital
-190.66
-341.30
-341.71
-95.91
-260.68
-310.56
128.87
-2.09
-82.37
-6.80
Cash after chg. in Working capital
240.63
346.76
150.29
139.37
-145.81
223.00
515.40
363.23
103.33
127.54
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-53.56
-58.62
-77.04
-55.97
-125.87
-88.75
-58.30
-39.29
-13.72
-9.80
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
582.59
-686.69
-2,224.83
51.87
4,077.09
806.54
-656.47
-941.00
-147.64
-218.93
Net Fixed Assets
709.54
-236.66
-535.93
-66.57
-119.10
-38.27
-18.46
-42.91
-26.86
-108.24
Net Investments
747.64
-143.27
-1,478.58
78.09
248.81
-508.54
77.70
653.52
-578.46
-103.41
Others
-874.59
-306.76
-210.32
40.35
3,947.38
1,353.35
-715.71
-1,551.61
457.68
-7.28
Cash from Financing Activity
-1,015.69
338.21
2,943.94
-421.25
-3,318.53
-990.03
89.36
850.09
91.64
13.43
Net Cash Inflow / Outflow
-246.03
-60.33
792.35
-285.98
486.88
-49.23
-110.01
233.03
33.60
-87.75
Opening Cash & Equivalents
515.08
1,110.74
298.91
586.00
132.02
211.93
325.17
79.00
45.88
179.34
Closing Cash & Equivalent
256.16
515.08
1,110.74
298.42
586.00
132.02
212.27
325.17
78.78
45.88

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Dec 09
Dec 08
Book Value (Rs.)
273.24
306.41
296.83
191.91
168.99
343.78
233.49
220.07
190.06
90.98
ROA
9.65%
5.79%
2.03%
0.04%
1.48%
14.07%
4.76%
3.66%
4.36%
4.78%
ROE
26.89%
16.53%
5.25%
0.09%
3.36%
42.16%
17.77%
13.87%
21.45%
36.41%
ROCE
16.09%
10.75%
7.54%
10.92%
7.76%
21.08%
12.82%
11.96%
10.93%
12.20%
Fixed Asset Turnover
1.07
1.27
1.47
1.21
0.61
0.27
0.82
0.72
0.80
0.87
Receivable days
102.66
96.77
90.73
114.71
114.80
193.43
65.68
86.42
105.79
97.90
Inventory Days
70.23
64.20
52.34
58.37
83.78
174.61
56.40
58.62
56.75
66.94
Payable days
116.23
117.33
75.51
76.81
112.69
253.28
92.58
119.83
129.46
131.06
Cash Conversion Cycle
56.67
43.64
67.55
96.27
85.89
114.76
29.50
25.22
33.08
33.78
Total Debt/Equity
1.03
1.35
1.34
0.78
0.54
0.79
1.94
1.58
1.79
3.15
Interest Cover
4.68
3.71
1.85
4.13
1.84
10.12
2.40
2.27
2.88
2.36

News Update:


  • Strides Pharma completes investment in Strides Consumer Healthcare Business
    24th Dec 2018, 12:14 PM

    India Life Sciences Fund III advised by ICP-III Investment Advisors has partnered with Strides

    Read More
  • Strides Pharma’s arm gets USFDA’s approval for Polyethylene Glycol, Electrolytes
    24th Dec 2018, 09:21 AM

    The company has 80 cumulative ANDA filings with USFDA of which 55 ANDAs have been approved including 11 approvals received in FY 19

    Read More
  • Strides to receive $42 million immediately from General Claims Escrow
    19th Dec 2018, 10:53 AM

    The claims in that arbitration were rejected in their entirety

    Read More
  • Strides Pharma’s arm gets USFDA’s approval for Lidocaine Ointment
    13th Dec 2018, 08:58 AM

    According to IQVIA MAT data, the US market for Lidocaine Ointment USP 5% is approximately $50 million

    Read More
  • Strides Pharma’s JV gets USFDA’s approval for Albendazole Tablets
    11th Dec 2018, 10:19 AM

    According to IQVIA MAT data, the US market for Albendazole Tablets USP 200 mg is approximately $100 million

    Read More
  • Strides Pharma gets nod to invest $15 million in its biotech arm
    23rd Nov 2018, 10:09 AM

    The company currently own 36.25% stake in Stelis, the former biopharma division of Strides

    Read More
  • Strides Pharma Science’s arm enters into agreement with SUDA Pharma
    9th Nov 2018, 09:21 AM

    Execution of Strides’ generic product pipeline for the US is nearing completion and is expected to have 150 plus ANDA filings by 2021

    Read More
  • USFDA completes inspection at Strides Pharma Science’s Bangalore facility
    5th Nov 2018, 09:17 AM

    The inspection was completed successfully with Zero 483 observations

    Read More
  • Strides Pharma Science executes definitive agreements with ICP-III Investment Advisors
    31st Oct 2018, 12:03 PM

    The agreements aims to provide growth capital and focused attention to its Consumer Healthcare Business

    Read More
  • Strides Pharma Scien - Quarterly Results
    31st Oct 2018, 10:59 AM

    Read More
  • Strides’ arm receives USFDA’s approval for Gabapentin Capsules
    20th Oct 2018, 14:54 PM

    The product received approval in the first cycle of review of 10 months under the GDUFA II regime

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.